Best Life Sciences Companies in Singapore
The 299 best Life Sciences companies in Singapore in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: TauRx.
Singapore's Life Sciences sector draws serious capital, and this directory ranks 299 companies by disclosed equity funding and recent momentum to show you exactly where it's concentrated. Total disclosed funding sits at $2.8 billion across the tracked cohort, with two unicorns already in the mix. Cerecin leads the field by a wide margin at $237 million raised, followed by Nuevocor at $36 million and Galatek at $30 million. That gap between Cerecin and the next tier isn't noise. It reflects how capital in this market clusters around clinical-stage bets with global licensing potential. The global life sciences market was pegged at roughly $167.8 billion with a 10.2% CAGR, and Singapore's funding trajectory fits that curve.
What's worth watching beyond the top names? SEEDS Capital and EDBI are the most active backers here, which tells you the public co-investment infrastructure is still doing real work. I'd also flag the broader digital health signal: median app install growth across healthcare and life sciences apps is running at roughly 43% year over year, a sign that distribution channels are opening fast. Meanwhile, consolidation is moving quickly across the Asia-Pacific life sciences supply chain, which only sharpens Singapore's strategic position as a regional hub. The funding spread here is real, earned, and worth mapping carefully.
- What Drives San Diego's Life Sciences Industry
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Singapore
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TauRx 🦄 Developer of treatments for neurodegenerative diseases | $434M | 43 mo ago | 78 | 2002 | K Seng Co-Founder | Craft CMSPHPYii+13 | — | — |
| 2 | MEGAROBO 🦄 Provider of robotic solutions for industrial laboratory automation 53Moat top 15%Funding top 29%Talent top 38%Global top 44% All 8 signals ▾Moattop 15% Fundingtop 29% Talenttop 38% Globaltop 44% Growthtop 45% Markettop 49% Techbottom 35% Newsbottom 22% Moat: Editorial + unicorn rating 9/10 · Unicorn Funding: Raised $427M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $427M | 48 mo ago | — | 2016 | Daniel Huang Co-Founder | PHPBootstrapTengine+7 | — | 1 partnership · 1 award |
| 3 | Tessa Developer of next-generation cell therapies for cancer | $256M | 48 mo ago | 183 | 2011 | — | — | — | — |
| 4 | Cerecin Developer of medical food and drugs for Alzheimer's disease | $237M | 24 mo ago | 40 | 2001 | Charles Stacey CEO & President | — | 6 patents Predictive pharmacokinetic modeling for drug‑induced ketogenesis using AI decision‑support systems | — |
| 5 | Mirxes Developer of miRNA based test for the detection of cancer | $207M | 34 mo ago | 400 | 2014 | Zhou Lihan Co-Founder & CEO | WordPressApple iCloud MailMicrosoft 365+36 | — | 1 launch · 1 partnership |
| 6 | Esco Lifesciences Manufacturer of biopharma equipment & IVF medical devices, and service provider for life science tools | $200M | 60 mo ago | 5 | 1978 | Estelle Couriol Founder & Creative director ESCO | SalesforcePHPCentOS+25 | — | 1 expansion |
| 7 | Hummingbird Bioscience Developer of antibody drugs for cancer treatment | $150M | 61 mo ago | 112 | 2015 | Jerome Boyd-Kirkup Co-Founder & CSO | WordPressMySQLPHP+20 | 151 patents Engineered antigen-binding proteins for cancer immunotherapy targeting HER3, B7‑H3, Trop2. | — |
| 8 | ASLAN Pharmaceuticals Targeted small molecules for cancer treatment | $100M | 39 mo ago | 34 | 2010 | Kingsley Leung | — | 122 patents Immunotherapy for atopic dermatitis via anti‑IL‑13R antibodies and DHODH inhibitors | — |
| 9 | Engine Biosciences Developer of platform technology for combinatorial genetics discovery | $86M | 31 mo ago | 39 | 2014 | Jeffrey Lu Co-Founder And Ceo | WordPressMySQLPHP+20 | 31 patents PKMYT1 kinase inhibitors, tau-modulating agents, and synthetic‑lethality cancer therapeutics | — |
| 10 | Fourier Intelligence Provider of rehabilitation robotics development & redefining services | $83M | 52 mo ago | 537 | 2015 | Zen Koh Co-Founder & CEO | — | — | — |
| 11 | Medisix Therapeutics Developer of CAR-T therapies to treat cancer and autoimmune diseases | $63M | 62 mo ago | 23 | 2017 | Dario Campana Founder | — | 21 patents CAR‑T cell engineering and manufacturing with CD3 blockade and multi‑protein regulation | — |
| 12 | AWAK Developer of portable digital dialysis devices | $60M | 33 mo ago | 81 | 2007 | Kok Beng Neo Co-Founder & CEO | — | — | — |
| 13 | Lion TCR Developer of T-cell therapeutics for the treatment of viral infections | $60M | 35 mo ago | 32 | 2015 | Xiaoming Peng CEO | — | 32 patents Engineered T‑cell receptors and antisense oligos for antiviral/immune cell therapies | — |
| 14 | ImmunoSCAPE Immune profiling services through their proprietary platform | $39M | 44 mo ago | 43 | 2016 | — | — | — | — |
| 15 | Nuevocor Developer of gene therapies for the treatment of cardiovascular disease | $36M | 13 mo ago | 28 | 2021 | Yin Lee Co-Founder | WixSentryBootstrap+13 | — | 1 partnership · 1 expansion |
| 16 | Galatek Developer of automation solutions for life science and semiconductor industries | $30M | 5 mo ago | — | 2025 | David Tian Founder & CEO | PHPanime.jsLayui+12 | — | 1 expansion |
| 17 | AUM Biosciences Developer of small molecules for cancer treatment | $28M | 56 mo ago | 18 | 2018 | Vishal Doshi Founder& CEO | WordPressMySQLPHP+16 | — | — |
| 18 | MerLion Pharmaceuticals Developer of fluoroquinolone-based therapeutics for bacterial infections | $20M | 61 mo ago | 10 | 2002 | — | — | 35 patents Finafloxacin antibiotic formulations for ocular, topical, and urinary infection treatments | — |
| 19 | Allozymes Developer of enzyme engineering platform for biosolutions across diverse industries | $20M | 25 mo ago | 22 | 2019 | Akbar Vahidi Co-Founder & CTO | WebflowYouTubeSwiper+14 | — | — |
| 20 | Biobot Surgical Developer of surgical automation devices 48Innovation top 27%Talent top 28%Growth top 32%Patents top 32% All 10 signals ▾Innovationtop 27% Talenttop 28% Growthtop 32% Patentstop 32% Fundingtop 38% Moattop 47% Fin. healthtop 49% Globalbottom 41% Marketbottom 26% Techbottom 16% Innovation: 42 patents (top 32% of patent-holders) · 18 filings since 2022 vs 11 in 2017-21 Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 48/100 | $18M | 2 mo ago | 1 | 2010 | Yap Loong Founder | WordPressMySQLPHP+8 | 42 patents Surgical needle guidance and locking mechanisms for precise minimally invasive procedures | 2 partnerships |
| 21 | Alternative Bio Developer of novel therapeutics to treat intractable cancers | $15M | 42 mo ago | — | — | Fei Lan Co-Founder | — | — | — |
| 22 | Axcynsis Therapeutics Developer of immunotherapies for cancer treatment | $15M | 49 mo ago | 23 | 2022 | Zou Bin Founder & CEO | — | 12 patents Targeted antibody therapeutics and ADCs for cancer biomarkers HCLDN6, ALPP/ALPPL2. | — |
| 23 | Biosensors International Products for interventional cardiology and critical care procedures | $15M | 233 mo ago | — | 1990 | Yoh Lu Founder | DrupalPHPCentOS+8 | — | 2 job openings |
| 24 | Spectrumedics Manufacturer of a therapeutic device for the treatment of arterial vascular calcification | $15M | 49 mo ago | — | 2018 | Peng Huiqun Co-Founder | — | — | — |
| 25 | EndoMaster Developer of robot-assisted surgical system for endoscopic surgeries | $15M | 111 mo ago | 25 | 2011 | — | — | — | — |
| 26 | NSG BioLabs Operator of shared BSL-2 laboratory and office spaces for life science | $14M | 25 mo ago | 6 | 2019 | Daphne Teo Founder & CEO | WordPressMySQLPHP+22 | — | 1 launch · 1 partnership · 1 award |
| 27 | Sunbird Bio Developer of blood-based diagnostic tests for neurological disorders | $14M | 20 mo ago | 12 | 2020 | Carine Lim Co-Founder | WixSentryBootstrap+11 | — | — |
| 28 | Carmine Therapeutics Developer of gene-based therapies using blood cell vesicle-based drug delivery systems | $14M | 44 mo ago | 33 | 2019 | Jiahai Shi Co-Founder | — | 20 patents Targeted nucleic‑acid delivery via engineered extracellular vesicles for therapy | — |
| 29 | Nalagenetics Developer of genetic test kits for precision medicine | $14M | 50 mo ago | 62 | 2016 | Jianjun Liu Co-Founder | Apple iCloud MailMicrosoft 365Node.js+28 | — | 1 launch · 1 partnership |
| 30 | Gero Developer of reverse engineering technology for controlling aging | $14M | 32 mo ago | 39 | 2015 | Peter Fedichev Co-founder & CEO | TildaGoogle Font APIYandex.Metrika+7 | — | — |
| 31 | Moon Technologies Developer of an augmented reality vision screening device | $11M | 4 mo ago | — | 2003 | Jian Ming T Co-Founder | — | — | — |
| 32 | AMILI Provider of gut microbiome data insights, analytics, tests, and therapeutics | $10M | 36 mo ago | 51 | 2019 | David Ong Co-Founder | Cart FunctionalityNode.jsSvelteKit+9 | — | 1 internship · 2 launchs |
| 33 | Endofotonics Raman spectroscopy-based endoscopic system | $8M | 72 mo ago | 19 | 2014 | Cheng Kum Co-Founder & CEO | — | — | — |
| 34 | SCG Developer of immunotherapies for pathogenic infections and cancers | $8M | 38 mo ago | 12 | 2017 | — | Microsoft ASP.NETTengineModernizr+3 | — | — |
| 35 | Qritive AI-based oncology diagnostic solution based on microscopic images & patient data | $8M | 41 mo ago | 31 | 2017 | Kavita Butalia Co-Founder | WixSentryYouTube+20 | — | 1 partnership |
| 36 | Cordlife Provider of cord blood and cord lining banking and newborn metabolic screening | $7M | 271 mo ago | 111 | 2001 | — | DrupalPHPUbuntu+14 | — | — |
| 37 | HistoIndex Provider of AI powered digital pathology platform for fibrosis analysis | $7M | 13 mo ago | 20 | 2010 | Dean Tai Co-Founder & Chief Scientific Officer | WordPressMySQLPHP+26 | — | — |
| 38 | NDR Medical Technology AI-enabled robotic-based device for image-guided procedures | $6M | 60 mo ago | 19 | 2014 | Alan Goh Co-Founder & CEO | — | 12 patents Medical robotic control and navigation systems for precise elongated tool trajectory and alignment. | — |
| 39 | DotBio Provider of antibody-based therapies | $6M | 34 mo ago | 12 | 2018 | Ignacio Asial Founder & CEO | — | — | 1 award |
| 40 | SynPhNe Developer of wearable technology designed to aid rehabilitation for disabilities | $5M | 27 mo ago | — | 2011 | John Heng Co-Founder | — | — | — |
| 41 | KYAN Technologies Provider of personalized medical solution, drug screening, and computational analysis services | $5M | 43 mo ago | 6 | 2022 | Hugo Saavedra Co Founder | WordPressMySQLPHP+24 | — | — |
| 42 | Breathonix Developer of a breath test system for the detection of COVID-19 | $5M | 60 mo ago | 10 | 2019 | Zhunan Jia Co-Founder & CEO | — | — | — |
| 43 | Pedra Developer of tissue perfusion monitoring technology | $5M | 68 mo ago | 3 | 2013 | Kareen Looi CEO | — | — | — |
| 44 | Albatroz Therapeutics Developer of therapeutic antibodies for cancer and arthritis | $3M | 37 mo ago | — | 2020 | Frederic Bard Co-Founder & CEO | — | 8 patents Calnexin-targeted antibodies for IBD therapy and diagnostic detection | — |
| 45 | Cellivate Technologies Developer of nanotechnology to study issues related to growing cells 11Moat top 48%Talent bottom 49%Funding bottom 48%Global bottom 37% All 6 signals ▾Moattop 48% Talentbottom 49% Fundingbottom 48% Globalbottom 37% Marketbottom 24% Newsbottom 18% Moat: Editorial + unicorn rating 4/10 · 8 curated direct competitors tracked Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 11/100 | $2M | 14 mo ago | 8 | 2019 | Viknish Krishnan-Kutty Founder & CEO | — | — | — |
| 46 | Choir CRM Provider of cloud-based CRM software for life sciences companies | $2M | 32 mo ago | — | 2022 | Henry Sun Co-Founder | — | — | — |
| 47 | NousQ Developer of a robotic surgical applicator for ear tube surgery. | $2M | 35 mo ago | 10 | 2021 | Gan Wee Co-Founder | WixSentryBootstrap+11 | — | — |
| 48 | Bioactivx Developer of synthetic biomaterial platform technology for soft and hard tissue repair | $1M | 7 mo ago | — | 2023 | Mickey Cheong Co-Founder & COO | — | — | 3 job openings · 1 expansion |
| 49 | Craft Health Provider of 3D printed personalized pharmaceuticals and nutraceuticals with end-to-end solutions | $1M | 25 mo ago | 9 | 2019 | Wei Goh Co-Founder & CEO | — | 11 patents 3D‑printed oral dosage forms enabling extended and colon‑targeted drug release | — |
| 50 | Moom Health Developer of personalised women health supplements | $854K | 14 mo ago | 8 | 2021 | Maya Kale Co-Founder | Cart FunctionalityShopifyBootstrap+15 | — | 9 job openings |
Top 12 Life Sciences companies in Singapore
#1
Series C · Singapore, Singapore · founded 2010 · 1 employees$17.9Mraised▾
Developer of surgical automation devices. The products include robotic transperineal biopsy device (rTPB), developed through collaborative partnership that enables surgeons to extract prostate biopsy tissues through 2 small needle puncture incisions on the perineal skin.
- Apr 2026Series C$7.8M
- Mar 2024Series B$17.9M
#2
Series A · Singapore, Singapore · founded 2025$30Mraised▾
Developer of automation solutions for life science and semiconductor industries. The company provides liquid handling workstations, high content cell imaging systems, and three-dimensional disease model technology. It also offers precision motion control, advanced optics, and artificial intelligence vision platforms. The company focuses on cell gene editing, high-throughput drug screening, and synthetic biology.
- Dec 2025Series A$30M
#3
Series A · Singapore, Singapore · founded 2003$11.3Mraised▾
Developer of an augmented reality vision screening device. This device facilitates self-administered ocular screening, enabling rapid risk stratification for leading causes of blindness. It performs visual acuity tests and is designed for patient-led assessments, improving accessibility and convenience. The device aims to increase testing capacity and reduce costs associated with vision screening. Further ocular screening tests are under development.
- Feb 2026Series A$8.7M
- Nov 2025Seed$2.6M
#4
Series B · Singapore, Singapore · founded 2021 · 28 employees$35.6Mraised▾
Developer of gene therapies for the treatment of cardiovascular disease. The company's lead product is a recombinant adeno-associated virus‑based gene therapy for patients suffering from dilated cardiomyopathy due to mutations in the Lamin A/C (LMNA) gene.
- May 2025Series B$45M
- Nov 2022Series B$11.6M
- Jun 2021Series A$24M
#5
Series C · Singapore, Singapore · founded 2001 · 40 employees$237Mraised▾
Developer of medical food and drugs for Alzheimer's disease. The food contains ketone bodies, medium-chain triglycerides, and helps in memory and cognition. It also offer aricaprilin for the treatment of Alzheimers, an oral formulation of a medium-chain triglyceride that induces ketosis and improves mitochondrial metabolism.
- Jun 2024Series C$3.7M
- Aug 2022Series C$7.2M
- Oct 2021Series C$30M
- Feb 2021Series C$10M
#6
Seed · Singapore, Singapore · founded 2023$1.4Mraised▾
Developer of synthetic biomaterial platform technology for soft and hard tissue repair. It focuses on creating medical implants that support the body’s natural healing processes. Its initial product is a skin substitute designed to close acute and chronic wounds. The company’s pipeline includes advanced wound-care solutions designed to accelerate healing and fight infection.
- Nov 2025Seed$1.4M
#7
Series A · Singapore, Singapore · founded 2010 · 20 employees$6.9Mraised▾
Provider of AI powered digital pathology platform for fibrosis analysis. The platform utilizes Second Harmonic Generation (SHG) and Two-Photon Excitation (TPE) microscopy to capture high-resolution images of unstained tissue samples to quantify fibrosis and other morphological features. The technology accelerates therapeutic development and clinical trial by providing translatable data from preclinical studies to clinical trials and enhancing clinical diagnostics. It supports advancements and regulatory approvals across the drug development and clinical diagnostic value chain.
- May 2025Series A$6.9M
- Jun 2013Seed—
#8
TauRx 🦄Series E · Singapore, Singapore · founded 2002 · 78 employees$433.8Mraised▾
Developer of treatments for neurodegenerative diseases, specifically Alzheimer's disease and frontotemporal dementia. The company focuses on the development and commercialization of treatments targeting tau pathology. Research and development efforts include clinical trials and collaborations to advance therapeutic options. The company's pipeline includes a drug candidate currently under regulatory review for mild cognitive impairment and mild to moderate Alzheimer's disease.
- Nov 2022Series E$119M
- Jul 2016Series D$117.8M
- Oct 2015Series D$135M
- Mar 2013Series B$10.5M
#9
Series B · Singapore · founded 2020 · 12 employees$14Mraised▾
Developer of blood-based diagnostic tests for neurological disorders. The company’s technology detects proteins associated with neurological disorders. These tests support diagnosis and treatment of diseases, such as Alzheimer's, Parkinson's, and ALS. The technology aims to provide researchers and clinicians with diagnostic information for differential diagnoses.
- Oct 2024Series B$14M
#10
Public · Singapore, Singapore · founded 2014 · 400 employees$207Mraised▾
Developer of miRNA-based test for the detection of cancer. The company's core technology is a highly specific RT-PCR primer that imposes a conformational restriction on miRNA for efficient binding to mature, but not precursor miRNAs, coupled with optimized RT-PCR reagents. These primers confer high specificity, sensitivity, and enhanced signal-to-noise ratio in amplification reactions. The company manufactures miRNA detection and quantification kits for research and is developing miRNA-based liquid biopsy kits for gastric cancer, lung cancer, and breast cancer detection.
- Jul 2023Series D$50M
- Oct 2021Series C$87M
- Jul 2021Series C$77M
- Aug 2019Series A$40M
#11
MEGAROBO 🦄Series C · Singapore, Singapore · founded 2016$427.3Mraised▾
Provider of robotic solutions for industrial laboratory automation. It leverage robotics and AI technologies to enhace productivity and productivity in various life sciences applications, including drug discovery and clinical diagnostics. It provides solutions for throughput drug screening, automated cell line development, and synthetic biology.
- Jun 2022Series C$300M
- May 2021Series B$65M
- Feb 2021Series B$30M
- Nov 2020Series B$30M
#12
Seed · Singapore, Singapore · founded 2019 · 8 employees$2Mraised▾
Developer of nanotechnology to study issues related to growing cells. It offers a product called ProCYTE, which is designed to improve cell growth and adhesion. It caters to biotechnology.
- Apr 2025Seed—
- Jan 2025Seed$17.5K
- Aug 2024Seed$1M
- May 2023Seed$1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Singapore
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 281 Singapore-affiliated papers.
- Ministry of Education70
- National University of Singapore38
- Nanyang Technological University35
- Agency for Science, Technology and Research25
- Ministry of Health25
- In vivo10
- Gene7
- Messenger RNA6
- Immune system5
- Cell biology4
- Bacteria7
- In vivo5
- Yield (engineering)4
- Synthetic biology4
- Gene4
- In vivo4
- Production (economics)4
- Disease3
- Human health3
- Antibiotic resistance2
Where biotechnology is researched across Singapore
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.